Humira biosimilars Hyrimoz, Hulio show ‘positive clinical outcomes’ for patients with IBD

Two adalimumab biosimilars, adalimumab-adaz and adalimumab-fkjp, demonstrated safety and effectiveness in patients with Crohn’s disease and ulcerative colitis, according to a study in PLOS One.“The adalimumab biosimilars [Hulio (adalimumab-fkjp, Fujifilm Kyowa Kirin Biologics)] and [Hyrimoz (adalimumab-adaz, Sandoz)] are now available for clinical use in IBD in many countries all over the world,” Martin Wasserbauer, MD, of the department of internal medicine at Charles University and Motol University Hospital in Prague, and colleagues wrote. “Extensive laboratoryRead More

Generated by Feedzy